The Diverse Function of PD-1/PD-L Pathway Beyond Cancer
2019-10-04
SCID: 54.1/7cqcadxs
Discuss with AI
Figures from the paper
Abstract (AI)
The recent success of PD-1 and PD-L1 blockade in cancer therapy illustrates the important role of the PD-1/PD-L1 pathway in the regulation of antitumor immune responses. However, signaling regulated by the PD-1/PD-L pathway is also associated with substantial inflammatory effects that can resemble those in autoimmune responses, chronic infection, and sepsis, consistent with the role of this pathway in balancing protective immunity and immunopathology, as well as in homeostasis and tolerance. Targeting PD-1/PD-L1 to treat cancer has shown benefits in many patients, suggesting a promising opportunity to target this pathway in autoimmune and inflammatory disorders. Here, we systematically evaluate the diverse biological functions of the PD-1/PD-L pathway in immune-mediated diseases and the relevant mechanisms that control these immune reactions.
Key Findings
1
PD-1/PD-L1 pathway critically regulates antitumor immune responses, as evidenced by success of PD-1 and PD-L1 blockade in cancer therapy.
2
Signaling via the PD-1/PD-L pathway is associated with substantial inflammatory effects resembling autoimmune responses, chronic infection, and sepsis.
3
The PD-1/PD-L pathway balances protective immunity and immunopathology, contributing to immune homeostasis and tolerance.
4
The paper systematically evaluates diverse biological functions and mechanisms of the PD-1/PD-L pathway in immune-mediated diseases.
5
Therapeutic targeting of PD-1/PD-L1, successful in many cancer patients, suggests potential opportunities to treat autoimmune and inflammatory disorders.
Research Object
PD-1/PD-L pathway (PD-1 and PD-L1 signaling axis)
Research Subject
Diverse biological functions and mechanisms of PD-1/PD-L signaling in regulating immune responses across cancer, autoimmune and inflammatory diseases, chronic infection, and sepsis
Publication Details
Publication Date
2019-10-04
Journal
Publisher
ISSN
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai5
PD-1 and Its Ligands in Tolerance and Immunity2008
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review2017
The future of immune checkpoint therapy2015
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer2012
Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation2000